Medtronic (MDT) Results Match Preannouncement Commentary, UBS Reiterates Buy Rating

February 24, 2021 6:15 AM EST
Get Alerts MDT Hot Sheet
Price: $126.21 +0.24%

Rating Summary:
    26 Buy, 12 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 20 | New: 68
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

UBS analyst Matthew Taylor reiterated a Buy rating and $130.00 price target on Medtronic (NYSE: MDT) after the company reported FY3Q21 results (Jan), with sales of $7.78B -1% organic (cons.$7.77B) and EPS of $1.29 (-10%) vs. cons. $1.15. On January 11, management noted that results could be roughly flat instead of flat to slightly up due to impact from CV-19 surges in Dec. and Jan and the reported -1% organic decline matched these statements. Despite this, MDT noted q/q improvements in revenue and earnings and cited continued share gains in an increasing number of businesses.

The analyst stated "We reiterate our Buy rating on shares of MDT and continued to be impressed by the company's progress in a number of segments, showing strong relative performance and execution during the pandemic; we are excited about MDT's pipeline as well."

For an analyst ratings summary and ratings history on click here. For more ratings news on click here.

Shares of closed at $118.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

UBS, Earnings